Traders looked unfavorably on Apellis Pharmaceuticals (Nasdaq: APLS) stock on Monday, after the company's report into the safety of its newly-approved Syfovre (pegcetacoplan) detailed a small number of retinal vasculitis cases.
Apellis stock dropped by a fifth over the course of the day, as the firm revealed seven people developed the rare complication following injections of the medicine.
The latest drop comes several weeks after initial reports of the possible adverse events came out, causing the company’s market cap to fall precipitously.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze